← All trials

NCT06854601

Phase 3Interventional

Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.

View on ClinicalTrials.gov ↗

Timeline

Start date
Jul 13, 2019
Primary completion
Jul 13, 2020
Completion date
Jul 13, 2020
First posted
Mar 3, 2025
Last posted
Aug 17, 2025
Enrollment
333
Arms / groups
3 / —
Source
AACT · ctgov ingestion

Sponsors

Drugs studied

Indications studied

CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.